TG Therapeutics, Inc. Provides Business Update and Reports Third Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
TG Therapeutics (TGTX) PT Raised to $36 at SunTrust Robinson Humphrey; Catalyst Rich 6-18 Months
November 9, 2017 7:47 AM ESTSunTrust Robinson Humphrey raised its price target on TG Therapeutics (NASDAQ: TGTX) to $36.00 (from $28.00) while maintaining a Buy rating.
Analyst Suneja Yatin sees the next 6-18 months are a catalyst-rich period for TGTX, with multiple N-T inflection points: (1) UNITY-CLL pivotal ORR... More
